Table 1: Baseline characteristics of our study population.
| Age (± SD) | 73.0 ± 9.7 years |
| Men, n (%) | 14 (56.0) |
| Arterial Hypertension, n (%) | 18 (72.0) |
| Diabetes, n (%) | 6 (24.0) |
| Atrial fibrillation, n (%) | 6 (24.0) |
| Betablocker therapy, n (%) | 6 (24.0) |
| Diuretics therapy, n (%) | 11 (44.0) |
| Antiplatelet therapy, n (%) | 6 (24.0) |
| Statins therapy, n (%) | 12 (48.0) |
| Oral antidiabetic therapy, n (%) | 6 (24.0) |
| BMI, median (percentil 25, percentil 75) | 29 (27, 32) |
NYHA, n (%) Class I, n (%) Class II, n (%) Class III, n (%) |
2 (8.0) 21 (84.0) 2 (8.0) |
| Preserved myocardial function, n (%) | 23 (92.0) |
| Total surgical time (min) | 192.2 ± 64.2 |
| ECC time (min) | 82.9 ± 21.0 |
| Aortic clamp time (min) | 70.5 ± 16.0 |
| Mechanical ventilation time after surgery (hours) | 7.3 ± 5.7 |
| Endotracheal intubation time (hours) | 10.0 ± 6.7 |
| Length of stay in Postoperative Care Unit (hours) | 52.0 ± 57.0 |
| Length of stay at hospital after surgery (days) | 6.0 ± 2.7 |
| Peak of Troponin I I (ng/dL) | 6.4 ± 3.6 |
| Leucocyte peak, × 103/ml | 9.3 ± 3.6 |
| Electric defibrillation required after CBP n (%) | 5 (20.0) |
| Biologic Prosthesis, n (%) | 16 (64.0) |
| Low cardiac output after surgery, n (%) | 4 (16.0) |
| Neurologic impairment, n (%) | 2 (8.0) |
| Complications after discharge, n (%) | 4 (16.0) |
| Platelet transfusion, n (%) | 7 (28.0) |
| Fresh frozen plasma transfusion, n (%) | 6 (24.0) |
Red cell transfusion (n = 25): 0, n (%) 1-3, n (%) > 3, n (%) |
6 (24.0) 12 (48.0) 7 (28.0) |
Anesthetic agent for induction (n = 25): Sevoflurane, n (%) Propofol, n (%) Etomidate, n (%) |
10 (40.0) 10 (40.0) 5 (20.0) |
Anesthetic agent for maintenance (n = 25): Sevoflurane, n (%) Propofol, n (%) |
19 (76.0) 6 (24.0) |
Anesthetic agent during CBP (n = 25): Sevoflurane, n (%) Propofol, n (%) Midazolam, n (%) |
10 (40.0) 14 (56.0) 1 (4.0) |